Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

NCT06915766 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Systemic Mastocytoses, Indolent
Systemic Mastocytoses, Aggressive

Interventions

DRUG: Bezuclastinib

Sponsor

Cogent Biosciences, Inc.